Dana-farber Cancer Institute

This study is for children and teens newly diagnosed with acute lymphoblastic leukemia (ALL), a cancer of the blood that is fatal without treatment. The trial uses updated risk factors to tailor chemotherapy strength and tests a new way to dose the drug pegaspargase based on bloo…

This early-phase study tests whether a personalized vaccine made from a patient's own tumor mutations can safely boost the immune system to fight glioblastoma, an aggressive brain cancer. About 56 newly diagnosed patients receive the vaccine along with radiation and sometimes the…

This study tests two drugs, niraparib and dostarlimab, given before surgery to people with BRCA or PALB2 gene mutations and early-stage breast cancer. The goal is to see if the treatment shrinks tumors and boosts immune activity. 62 participants are enrolled, and the study is act…

This study tests a combination of two drugs, duvelisib and venetoclax, in people with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) or Richter's Syndrome. The goal is to see if the combo can shrink or control the cancer. About 55 adults who have already tried at le…

This early-phase study tested a personalized vaccine (NeoVax) made from a patient's own tumor mutations, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 11 people with advanced melanoma that could not be removed by surgery. The main goal was to check safety a…

This study looks at whether a 16-week home-based exercise program can slow prostate cancer growth in Black men who are monitoring their cancer without immediate treatment. The program involves high-intensity interval training (HIIT) done virtually with a coach. Researchers will m…

This early-phase study tests a personalized vaccine (NeoVax) combined with CDX-301 and standard immunotherapies (nivolumab or pembrolizumab) in 10 people with advanced melanoma. The goal is to find the safest dose and see if the vaccine boosts the immune system's attack on cancer…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin) helps people with metastatic triple-negative breast cancer live longer without their disease getting worse. About 78 participants with advanced cancer that has spread will rece…

This early-phase trial tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a stem cell transplant. The treatment combines a special donor cell infusion with an immunotherapy drug (ipilimumab) to fight the cancer. The main goal is to find the s…

This early-phase study tests a new drug, ACY-1215, combined with either ibrutinib or idelalisib in people whose chronic lymphocytic leukemia (CLL) has returned after prior treatment. The main goal is to find the safest dose and see if the combination helps control the disease. On…

This study tests whether a targeted chemotherapy drug (abemaciclib) and an immunotherapy drug (atezolizumab), alone or together, can shrink or slow advanced prostate cancer that has stopped responding to hormone therapy. Nineteen adult men with metastatic castration-resistant pro…

This study tests whether combining two drugs, olaparib and ceralasertib, can help control osteosarcoma that has come back or not responded to treatment. About 63 people aged 12 to 40 with this rare bone cancer will take part. The goal is to see if the combination can stop the can…

This study tests two immunotherapy drugs, nivolumab and ipilimumab, in 40 adults with recurrent or progressive meningioma (a type of brain tumor). The goal is to see if these drugs can stop the tumor from growing for at least six months. Participants receive either nivolumab alon…

This study tested a combination of two targeted drugs, osimertinib and selumetinib, in 25 people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal was to see how well the drugs shrink tumors and delay cancer growth. Participants had not received…

This study tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 100 adults with rare cancers of the urinary or reproductive systems. The goal is to see if the drugs can shrink tumors and control the disease. Participants have cancers that cannot be removed…

This early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. About 23 adults with CD22-positive B-ALL will receiv…

This early-phase study tests whether a new immune cell therapy, called memory-like natural killer (NK) cells, can be safely given to people with advanced kidney or bladder cancers. The treatment involves collecting a patient's own immune cells, boosting them with special proteins…

This study tests whether a newer drug, margetuximab, works better than the standard trastuzumab when combined with chemotherapy and pertuzumab before surgery for stage II-III HER2-positive breast cancer. About 174 participants will receive one of the two combinations. The main go…

This study tests two immunotherapy drugs, nivolumab and ipilimumab, given before surgery to people with squamous cell carcinoma of the oral cavity. The goal is to see if these drugs can shrink tumors and are safe to use. About 30 adults with stage T2 or higher tumors or lymph nod…

This study tests a program called ESCAPE, which combines smoking cessation support with education about lung cancer screening. It is for adults aged 55-77 who smoke heavily and have not had a lung scan. The goal is to see if the program helps more people quit smoking and get scre…

This study tests a drug called 177Lu-PSMA-617, which delivers radiation directly to cancer cells, in 24 people with advanced clear cell kidney cancer that has spread. The goal is to see if it shrinks tumors and how safe it is. Participants must have a specific marker (PSMA) on th…

This study is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink or control rare INI1-negative cancers in children and young adults. These cancers have come back or not responded to standard treatments. The goal is to see if the drugs help the…

This early-stage trial tests whether two oral drugs, talazoparib and tazemetostat, can be safely combined to treat metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that has spread and stopped responding to hormone therapy. About 35 participants w…

This study tests a targeted drug called osimertinib (Tagrisso) in 30 people with advanced EGFR-mutant non-small cell lung cancer who have not had this type of treatment before. The main goal is to understand why the drug stops working by comparing tumor samples taken before and a…

This study tests three drug combinations for people with a common type of advanced breast cancer (ER+/HER2-). The goal is to see if adding palbociclib or both palbociclib and avelumab to fulvestrant can help control the cancer longer. About 220 participants who have already recei…

This study tests a drug called daratumumab in people with early blood conditions (MGUS or smoldering myeloma) that may turn into active cancer. The goal is to see if the drug can deeply reduce or eliminate abnormal cells, potentially delaying or preventing progression. About 42 a…

This study tested whether adding the drug ruxolitinib to standard chemotherapy could help treat triple-negative inflammatory breast cancer, a rare and aggressive type. About 23 people took part. The goal was to see if the combination could reduce cancer activity before surgery an…

This study tested a combination of three drugs—nivolumab, bevacizumab, and rucaparib—in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the drugs could shrink tumors and control the disease. Participants …

This early-phase trial tests a new combination of drugs (ribociclib, everolimus, and dexamethasone) in children and young adults up to age 30 whose acute lymphoblastic leukemia has come back or not responded to standard treatments. The goal is to find the safest dose and see how …

This study looks at whether a 16-week exercise program can reduce inflammation in fat tissue for women who have finished treatment for early-stage breast cancer. About 100 participants will take part to see if movement helps lower markers linked to cancer recurrence. The goal is …

This study tested the drug clofarabine in 25 people with Langerhans cell histiocytosis (LCH) or related disorders that had returned or not improved with standard therapy. The goal was to see if the drug could shrink or eliminate disease. Participants received clofarabine and were…

This study is for older adults with HER2-positive breast cancer, a type that has too much of a protein called HER2. The trial tests a drug called T-DM1, which combines a targeted antibody with chemotherapy to kill cancer cells. The goal is to see if giving T-DM1 after surgery hel…

This study tests a combination of three drugs (bortezomib, lenalidomide, and dexamethasone) in people newly diagnosed with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see how well the drugs work together to control the disease. About 68 adult…

This study tested a targeted therapy called regorafenib in 8 people with advanced medullary thyroid cancer that had spread. The goal was to see if the drug could slow or stop cancer growth. Participants had already tried other treatments before joining.

This study looks at whether people with HER2-positive metastatic breast cancer who have done very well on anti-HER2 therapy (cancer controlled for 3+ years) can safely stop that treatment. Researchers will monitor those who stop versus those who continue to see if the cancer stay…

This early-phase study tests a personalized cancer vaccine designed to target each patient's unique tumor. 20 adults with follicular lymphoma will receive the vaccine along with pembrolizumab after standard rituximab treatment. The main goal is to see if the vaccine can be made q…

This study tests a drug called acalabrutinib in 49 people with central nervous system lymphoma that has returned or not responded to prior therapy. The goal is to find the safest dose and see how well it controls the cancer. Participants take the drug by mouth and are monitored f…

This study tests a combination of two targeted drugs (trastuzumab and pertuzumab) plus hormone therapy given after surgery for people with stage I hormone receptor-positive, HER2-positive breast cancer. The goal is to see if this approach helps prevent the cancer from coming back…

This study looks at whether removing the abnormal cells with surgery alone is enough for people with a very early, low-risk breast condition called DCIS. About 158 participants with small, low-grade DCIS will have only surgery and then be watched closely for any return of the con…

This study tests whether the chemotherapy drug lenalidomide can shrink or stop rare immune cell diseases called Langerhans cell histiocytosis, Erdheim-Chester disease, and histiocytic sarcoma. Twelve adults with active disease that needs treatment will receive lenalidomide and be…

This study tests a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) as an initial treatment for people with chronic lymphocytic leukemia (CLL) who have not had prior therapy. The goal is to see if this drug cocktail can wipe out cancer cells deep in the bo…

This study tested a drug called eribulin combined with standard chemotherapy given before surgery for a rare and aggressive type of breast cancer called HER2-negative inflammatory breast cancer. The goal was to see if this approach could eliminate all signs of cancer in the breas…

This study tests two immune-boosting drugs, ipilimumab and nivolumab, in people with classic Hodgkin lymphoma that has returned or not responded to prior therapy. The goal is to see if these drugs can shrink tumors when given alone or together. The trial enrolled 13 adults with m…

This early-phase study tests a combination of two drugs, olaparib and sapacitabine, in people with breast cancer that has spread and who have a BRCA gene mutation. The main goals are to find the safest dose and see if the combination shrinks tumors. About 10 participants are enro…

This study tested whether a daily low-dose injection of IL-2 can help control chronic graft-versus-host disease (cGVHD) in 35 people who had not improved with steroids. cGVHD is a condition where donor immune cells attack the recipient's body after a stem cell or bone marrow tran…

This study tests a combination of two drugs, copanlisib and venetoclax, in people with diffuse large B-cell lymphoma that has come back or not responded to prior treatments. The goal is to find the safest dose and see how well the drugs shrink tumors. About 48 adults will take pa…

This study tests whether adding the targeted drug ibrutinib to standard chemotherapy can completely clear chronic lymphocytic leukemia (CLL) from the bone marrow in younger, untreated patients. About 85 participants will receive the combination and be monitored for two years afte…

This study tests a new drug (IPI-145) added to a standard chemotherapy combination (FCR) for younger adults (ages 18-65) with untreated chronic lymphocytic leukemia (CLL). The goal is to see if the new combo is safe and can make the cancer disappear more completely, as measured b…

This early-stage study tests whether adding a chemotherapy drug (carboplatin) to a targeted radiation therapy (177Lu-PSMA-617) is safe and effective for men with advanced prostate cancer that has stopped responding to hormone therapy. About 37 participants will receive the combin…

This study tests two targeted drugs, T-DM1 and pertuzumab, given before surgery to people with early-stage HER2-positive breast cancer. The goal is to see if this combination can completely eliminate cancer cells in the breast, potentially reducing the need for more aggressive tr…

This study tests an investigational drug called AZD1775 in women whose uterine cancer has come back or persists. The goal is to see if the drug can shrink tumors or slow cancer growth. About 49 women with specific types of uterine cancer (serous carcinoma or carcinosarcoma) are t…

This study tests a targeted therapy called abemaciclib in people whose glioblastoma (a type of brain cancer) has come back. The goal is to see if the drug can reach the tumor and slow down its growth. About 45 adults with recurrent glioblastoma will take the drug before surgery a…

This study looks at whether different levels of exercise can help the hearts of young adults who survived childhood cancer and were treated with a type of chemotherapy called anthracyclines. About 20 survivors aged 18-39 will take part. The goal is to see if exercise can reduce h…

This study tests whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink tumors in people with a rare, advanced form of HER2-negative breast cancer that has many genetic mutations. The trial enrolled 30 participants and is no longer recruiting new patients…

This study tests a CAR-T cell therapy called cilta-cel in 20 people with high-risk smoldering myeloma, a pre-cancer condition. The treatment uses a patient's own immune cells, modified to attack myeloma cells, along with chemotherapy. The goal is to see if it is safe and can dela…

This early-phase study tests whether the drug talazoparib can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have a specific mutation in the cohesin complex. The study includes 13 participants who cannot receive standard intensive chemotherapy…

This study tested a two-step combination of drugs (rituximab/bendamustine followed by rituximab/cytarabine) in 23 adults with newly diagnosed mantle cell lymphoma who were healthy enough for a stem cell transplant. The goal was to see if this approach could achieve a higher compl…

This study tests whether combining two targeted drugs, ibrutinib and venetoclax, can shrink tumors in adults with Waldenström macroglobulinemia, a rare blood cancer. Participants must have a specific MYD88 gene mutation. The main goal is to see how many patients achieve a very go…

This early-phase study tests a genetically engineered virus (rQNestin34.5v.2) that targets and kills brain tumor cells. About 62 adults with recurrent malignant glioma will receive the virus injected directly into the tumor, sometimes with a drug called cyclophosphamide to boost …

This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and effective for people with advanced EGFR-mutant non-small cell lung cancer. About 48 participants will take both pills daily for up to 6 months. The goal is to see if the combination help…

This early-phase study tests a combination of two drugs (palbociclib and gedatolisib) in people with advanced lung, pancreatic, head & neck, or other solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the drugs can slow can…

This study tested the drug pembrolizumab in 18 people with aggressive lymphomas or rare immune cell cancers that had come back or not responded to other treatments. The goal was to see if the drug could shrink tumors. The trial was suspended, so results are limited.

This study tests a combination of two drugs, ibrutinib and obinutuzumab, in people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. The main goal is to check the safety of different doses. About 54 adults with CLL or a related lymphom…

This study tests whether people with chronic lymphocytic leukemia (CLL) can safely start venetoclax faster than the usual 5-week schedule. About 40 patients with new or returning CLL will take venetoclax daily with a quicker dose increase. The goal is to see if this faster approa…

This study looks at whether women with HER2-positive breast cancer who have a complete response to pre-surgery chemotherapy and antibody drugs can safely avoid more chemotherapy after surgery. Instead, they would receive only two antibody drugs (trastuzumab and pertuzumab) after …

This study looks at whether a blood test can detect key genetic changes in lung cancer and melanoma patients, potentially replacing the need for a tumor biopsy. Researchers will check how accurate the test is and how quickly it provides results. The goal is to make it easier to m…

This study tests whether metformin, a widely used diabetes medicine, can stop early blood conditions (MGUS and smoldering myeloma) from turning into multiple myeloma. About 60 people with higher-risk MGUS or low-risk smoldering myeloma will receive either metformin or a placebo p…

This study tests whether starting abemaciclib at a lower dose and gradually increasing it causes fewer side effects than the standard fixed dose. About 90 adults with early-stage, hormone receptor-positive breast cancer will take part. The goal is to see if this approach helps pe…

This study compares two brief video-based educational programs for young women (ages 19-49) who have completed cancer treatment and are dealing with sexual health issues. The goal is to see which program better helps improve sexual function and reduce emotional distress. Particip…

This study tests whether acupuncture can reduce nerve pain caused by chemotherapy in cancer survivors. About 255 people who have finished chemo will receive either real or sham acupuncture. The goal is to see if this drug-free approach can ease pain and improve daily life.

This study is for women aged 18-39 who were recently diagnosed with breast cancer (stages 0-3). It tests a web-based portal that provides symptom tracking, supportive care information, and peer support. The goal is to see if using the portal reduces common symptoms like vaginal d…

This study looks at whether a 16-week home exercise program can help Black and Hispanic patients with breast, colorectal, or prostate cancer become more active while on chemotherapy. Participants are split into three groups: supervised exercise via Zoom, unsupervised exercise, or…

This study tests whether talking to an exercise specialist over the phone can help breast and colorectal cancer survivors become more physically active after finishing chemotherapy. About 120 adults who completed treatment for early-stage cancer will be randomly assigned to recei…

This study tests whether yoga can reduce nerve pain caused by chemotherapy in cancer survivors. About 227 adults who finished chemo at least three months ago will either take yoga classes, attend educational sessions, or receive standard pain care. Researchers will compare pain l…

This study looks at whether a short exercise or mind-body program (like relaxation techniques) can help women with breast cancer feel less stressed and anxious while waiting for surgery. About 49 women will take part for 3-6 weeks before their operation. Researchers will also che…

This study looks at how people feel physically and emotionally after a breast biopsy for certain non-cancerous breast conditions (like atypical hyperplasia or DCIS). Over 900 participants from several hospitals answered questions about pain and quality of life, on average nearly …

This study looks at whether whole body MRI can help find cancers early in people with Li-Fraumeni syndrome, a genetic condition that greatly increases cancer risk. About 150 children and adults will get annual full-body scans for four years. The goal is to see if people return ea…

This study looks at how different ways of teaching families about genetics can help more people get tested for inherited pancreatic cancer risk. Up to 1,000 family members of pancreatic cancer patients will take part. Participants may provide a saliva sample for FDA-approved gene…

This study looks at 271 people with pancreatic cancer to find genetic mutations that might increase risk. Researchers will collect personal and family health history to build a tool that helps identify who is at higher risk. Participants also get genetic counseling and are asked …

This study tests a new imaging method that helps surgeons find and remove the very first lymph node that drains from a lung tumor. By targeting this node, doctors hope to better detect and remove cancer cells that may have spread. The study involves 57 adults with early-stage lun…

This study looks at whether testing the genes in a child's solid tumor can help doctors choose a targeted therapy that might work better. It involves 825 children and young adults up to age 30 whose cancer has come back or not responded to standard treatment. The goal is to see i…

This study looks at whether specialized testing (leukemia profiling) can help find targeted treatments for children and young adults up to age 30 with recurrent, hard-to-treat leukemias or myelodysplastic syndrome. An expert panel reviews the test results and may recommend a spec…

This study follows over 1,300 women aged 40 or younger who were just diagnosed with breast cancer. Researchers collect surveys, blood samples, and tumor tissue to learn about the disease, treatment side effects, and emotional challenges over at least 10 years. The goal is to bett…

This study is testing a tool called AYA-RISE, which includes a chatbot and an online portal, to help teenagers and young adults (ages 12-24) who have genetic conditions that raise their cancer risk. The goal is to see if the tool helps them better understand their cancer risk, ta…

This early-phase study tests the drug pembrolizumab in 60 adults with recurrent glioblastoma, an aggressive brain cancer. The main goal is to measure immune cell changes in the tumor and check for side effects. This is not a cure; it aims to gather information on how the drug wor…

This study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related conditions. The samples are stored in a tissue bank for researchers to study the causes and biology of these diseases. The …

This study looks at whether certain women with early-stage, low-risk breast cancer can avoid radiation after a lumpectomy. About 671 participants with small, hormone-receptor-positive, HER2-negative tumors are being followed for five years to see how often the cancer comes back i…

This study follows 253 adults aged 70 and older with early-stage breast cancer to learn how doctors make treatment decisions and how well patients stick to hormone therapy. Researchers will survey participants about barriers to care and treatment patterns. The goal is to find way…

This study looks at whether a heart screening program is practical for people who survived Hodgkin's disease after chest radiation. It involves 210 survivors who are at least 5 years past treatment. The goal is to find heart problems early and see if lifestyle changes or medicati…

This study looks at whether a blood test (liquid biopsy) can help predict how well children and young adults with Ewing sarcoma or osteosarcoma will do. Researchers will check for tumor DNA in the blood at diagnosis and see if it relates to cancer returning. The goal is to better…

This study looks at whether a genomic test called Prosigna can help doctors and patients choose the best treatment before surgery for HR+/Her2- breast cancer. About 60 women with early-stage or locally advanced breast cancer will participate. The main goal is to see how often the…

This study looks at whether a 12-week exercise program can affect certain markers in the breast tissue and blood of premenopausal women with dense breasts. Dense breast tissue is a known risk factor for breast cancer. The goal is to understand how physical activity might influenc…